FierceBiotech 3 mar 2026 FDA details rationale for rejecting rare disease gene therapy from Regenxbio
FierceBiotech 3 mar 2026 MindMaze seeks 'strategic alternatives,' eyes US expansion as 2 board members exit
FierceBiotech 3 mar 2026 Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug
FierceBiotech 3 mar 2026 AI musculoskeletal imaging medtechs Medimaps and Radiobotics pen merger deal
FierceBiotech 3 mar 2026 GLP-1s support heart attack recovery in rodents by relaxing tight blood vessels
FierceBiotech 3 mar 2026 HHS bans Claude AI tool as Trump seeks full government blacklisting of Anthropic
FierceBiotech 2 mar 2026 Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout
FierceBiotech 2 mar 2026 TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio
FierceBiotech 2 mar 2026 Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline
FierceBiotech 2 mar 2026 BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline
FierceBiotech 2 mar 2026 United Therapeutics’ phase 3 win tees up filing to challenge J&J in cardiac condition
FierceBiotech 2 mar 2026 UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy
FierceBiotech 2 mar 2026 Aardvark pauses phase 3 metabolic drug study over 'cardiac observations,' sinking sock
FierceBiotech 2 mar 2026 Roche reports another phase 3 multiple sclerosis win, but deaths add to safety questions
FierceBiotech 28 feb 2026 BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival
FierceBiotech 27 feb 2026 Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates